- Home
- QS vs MRNA Comparison
QS vs MRNA Comparison
Compare QS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- MRNA
- Stock Information
- Founded
- QS 2010
- MRNA 2010
- Country
- QS United States
- MRNA United States
- Employees
- QS N/A
- MRNA N/A
- Industry
- QS Auto Parts:O.E.M.
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QS Consumer Discretionary
- MRNA Health Care
- Exchange
- QS Nasdaq
- MRNA Nasdaq
- Market Cap
- QS 8.8B
- MRNA 9.2B
- IPO Year
- QS N/A
- MRNA 2018
- Fundamental
- Price
- QS $11.80
- MRNA $22.58
- Analyst Decision
- QS Sell
- MRNA Hold
- Analyst Count
- QS 7
- MRNA 15
- Target Price
- QS $8.07
- MRNA $36.69
- AVG Volume (30 Days)
- QS 38.2M
- MRNA 12.8M
- Earning Date
- QS 10-22-2025
- MRNA 11-06-2025
- Dividend Yield
- QS N/A
- MRNA N/A
- EPS Growth
- QS N/A
- MRNA N/A
- EPS
- QS N/A
- MRNA N/A
- Revenue
- QS N/A
- MRNA $2,232,000,000.00
- Revenue This Year
- QS N/A
- MRNA N/A
- Revenue Next Year
- QS N/A
- MRNA $10.38
- P/E Ratio
- QS N/A
- MRNA N/A
- Revenue Growth
- QS N/A
- MRNA N/A
- 52 Week Low
- QS $3.40
- MRNA $22.32
- 52 Week High
- QS $19.07
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- QS 36.79
- MRNA 36.79
- Support Level
- QS $14.84
- MRNA $24.18
- Resistance Level
- QS $16.22
- MRNA $25.06
- Average True Range (ATR)
- QS 1.44
- MRNA 1.42
- MACD
- QS -0.57
- MRNA -0.20
- Stochastic Oscillator
- QS 0.16
- MRNA 0.21
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.